ClinicalTrials.Veeva
Menu

Find clinical trials for Ovarian Cancer in Hanyang, Seoul

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma
Cancer
Carcinoma
Endometrial Cancer
Fallopian Tube Cancer
Breast Cancer
Triple Negative Breast Cancer

Ovarian Cancer trials near Hanyang, Seoul, KOR:

Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

adult subjects with CA125-associated, advanced recurrent epithelial ovarian, fallopian tube or peritoneal carcinoma (FIGO Stage III/IV) with...

Enrolling
Ovarian Cancer Stage IV
Ovarian Cancer by FIGO Stage
Drug: Bevacizumab
Drug: Carboplatin

Phase 1, Phase 2

CanariaBio

Seoul, Korea, Republic of and 5 other locations

of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...

Active, not recruiting
Relapsed Ovarian Cancer
Following Complete or Partial Response to Platinum Based Chemotherapy
Drug: Placebo to match olaparib 300mg
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Seoul, Korea, Republic of and 125 other locations

followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian ...

Active, not recruiting
Advanced Ovarian Cancer
Drug: Bevacizumab
Drug: Durvalumab placebo

Phase 3

AstraZeneca
AstraZeneca

Seoul, Korea, Republic of and 213 other locations

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....

Active, not recruiting
Advanced Ovarian Cancer
FIGO Stage III-IV
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Seoul, Korea, Republic of and 176 other locations

of alpelisib and olaparib compared with single agent cytotoxic chemotherapy in patients with platinum resistant or refractory high-grade serous ovarian...

Active, not recruiting
Ovarian Cancer
Drug: Alpelisib
Drug: Pegylated liposomal doxorubicin (PLD)

Phase 3

Novartis
Novartis

Seoul, Korea, Republic of and 102 other locations

This is a randomized phase II study of secondary cytoreductive surgery (CRS) in patients with relapsed ovarian cancer who have prog...

Enrolling
Ovarian Cancer
Drug Related Neoplasm/Cancer
Drug: chemotherapy
Procedure: secondary cytoreductive surgery

Phase 2

Korea University

Seoul, Korea, Republic of

A Phase 2/3 study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer...

Enrolling
Primary Peritoneal Cancer
Epithelial Ovarian Cancer
Drug: Luveltamab tazevibulin
Drug: Gemcitabine

Phase 2, Phase 3

Sutro Biopharma

Seoul, Korea, Republic of and 38 other locations

To evaluate the efficacy and safety of JPI-547, a PARP/TNKS dual inhibitor in Platinum-resistant, advanced/relapsed ovarian cancer ...

Active, not recruiting
Ovarian Cancer
Drug: JPI-547

Phase 2

Onconic Therapeutics

Gyeonggi-do, Korea, Republic of

This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and phar...

Enrolling
Solid Tumor
Epithelial Ovarian Cancer
Drug: Pegylated liposomal doxorubicin
Drug: Paclitaxel

Phase 1

K-Group Beta

Seoul, Korea, Republic of and 22 other locations

in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian...

Active, not recruiting
Primary Peritoneal Cancer
Fallopian Tube Cancer
Biological: Pembrolizumab
Drug: Gemcitabine

Phase 3

Mural Oncology

Seoul, Korea, Republic of and 117 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems